PLOD3

Across TCGA pan-cancer cohorts, PLOD3 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of PLOD3’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where PLOD3 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types PLOD3 is over-expressed in tumor.

CCRCC, HNSC, and PDAC are the cancer types where PLOD3 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PLOD3 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	IV	+1.458	<.001	12	view →
HNSC	All	IV	+1.210	<.001	12	view →
PDAC	Female	All	+0.975	<.001	11	view →
COAD	Female	III,IV	+0.613	<.001	11	view →
LSCC	Male	III,IV	+0.434	<.001	7	view →
LUAD	Male	All	+0.218	<.001	6	view →
OV	All	All	+0.278	.014	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

PLOD3–CCRCC

Open the CCRCC breakdown →